U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H21N2O3.Na
Molecular Weight 288.3179
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUCOLOME SODIUM

SMILES

[Na+].CCCCC1C(=O)[N-]C(=O)N(C2CCCCC2)C1=O

InChI

InChIKey=SGESMFOVCAMYRA-UHFFFAOYSA-M
InChI=1S/C14H22N2O3.Na/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10;/h10-11H,2-9H2,1H3,(H,15,17,19);/q;+1/p-1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C14H22N2O3
Molecular Weight 266.3361
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18445991 and http://www.genome.jp/dbget-bin/www_bget?drug+D01661

Bucolome (Paramidine) is a barbiturate derivative. It is a non-steroidal anti-inflammatory drug, which is used in the treatment of chronic articular rheumatism. It has been used as a uricosuric and/or anti-inflammatory agent in Japan since 1967. Bucolome acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 8.24 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
PARAMIDIN

Approved Use

Antirheumatic and antigout drug
PubMed

PubMed

TitleDatePubMed
Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.
2005 Apr
[Intraluminal ureteral hematoma complicating anticoagulant therapy].
2005 Jul
Patents

Patents

EP2448573A1
2
US2016058744
2
US2016090408
2

Sample Use Guides

In Vivo Use Guide
300 mg dose of bucolome once a day
Route of Administration: Oral
In Vitro Use Guide
Protein binding of furosemide (20 M) was significantly inhibited by 300 M bucolome in human serum
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:56:58 GMT 2023
Edited
by admin
on Sat Dec 16 10:56:58 GMT 2023
Record UNII
0QN61326HC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUCOLOME SODIUM
Common Name English
BARBITURIC ACID, 5-BUTYL-1-CYCLOHEXYL-, SODIUM SALT
Systematic Name English
BUCOLOME SODIUM SALT
Common Name English
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-BUTYL-1-CYCLOHEXYL-, SODIUM SALT (1:1)
Systematic Name English
SODIUM 5-BUTYL-1-CYCLOHEXYL-2,4,6-TRIOXOPERHYDROPYRIMIDINE
Systematic Name English
SODIUM BUCOLOME
Common Name English
Code System Code Type Description
FDA UNII
0QN61326HC
Created by admin on Sat Dec 16 10:56:58 GMT 2023 , Edited by admin on Sat Dec 16 10:56:58 GMT 2023
PRIMARY
PUBCHEM
23670498
Created by admin on Sat Dec 16 10:56:58 GMT 2023 , Edited by admin on Sat Dec 16 10:56:58 GMT 2023
PRIMARY
CAS
6891-28-7
Created by admin on Sat Dec 16 10:56:58 GMT 2023 , Edited by admin on Sat Dec 16 10:56:58 GMT 2023
PRIMARY
EPA CompTox
DTXSID30988620
Created by admin on Sat Dec 16 10:56:58 GMT 2023 , Edited by admin on Sat Dec 16 10:56:58 GMT 2023
PRIMARY
Related Record Type Details
Structure of BUCOLOME
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of BUCOLOME
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966